NCT07589374Not yet recruiting
Cf-PWV and TyG Index Study
Correlation Between Carotid-Femoral Pulse Wave Velocity and Triglyceride-Glucose Index and Its Derived Metrics
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This study aims to investigate how metabolic health is related to arterial stiffness and daily blood pressure patterns. High blood pressure is one of the leading causes of heart disease worldwide, but cardiovascular risk is not determined only by average blood pressure values. Changes in blood vessel structure and metabolic function also play an important role in the development of cardiovascular disease. Arterial stiffness reflects how flexible or rigid the arteries are. It can be measured using carotid-femoral pulse wave velocity (cf-PWV), which is considered a reliable and widely used method to assess vascular health. Increased arterial stiffness is associated with aging and higher cardiovascular risk. At the same time, metabolic factors such as insulin resistance and central obesity are strongly linked to vascular damage. The triglyceride-glucose (TyG) index is a simple measure derived from routine blood tests and has been shown to reflect insulin resistance. Additional derived indices that combine TyG with body measurements (such as waist circumference and body mass index) may provide an even more comprehensive evaluation of metabolic risk. Another important aspect of cardiovascular regulation is how blood pressure changes throughout the day. Blood pressure naturally rises in the morning after waking, a phenomenon known as the morning blood pressure surge. When this increase is excessive, it has been associated with a higher risk of cardiovascular events such as stroke and heart attack. This study will evaluate the relationship between metabolic indices, arterial stiffness, and morning blood pressure patterns in adults undergoing ambulatory blood pressure monitoring as part of routine clinical care. The study will include both previously collected data and new participants evaluated using standardized methods. No additional interventions will be performed, and all data will be collected as part of routine clinical evaluation. The results of this study may help improve cardiovascular risk assessment by integrating simple metabolic markers with vascular measurements and daily blood pressure behavior, potentially allowing earlier identification of individuals at higher risk.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 2 May 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- Hospital de Base
- Diseases
- High blood pressure
- NCT number
- NCT07589374
What you commit to
- Study type: Observational
- Planned participants: 800
- From 1 Jul 2026 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of antihypertensive medication at the time of evaluation;
Other illness
- Cardiac arrhythmias that may interfere with accurate blood pressure or pulse wave velocity measurements;
- Presence of severe vascular disease or conditions affecting arterial waveform assessment;
Lab values
- Missing essential clinical, laboratory, or hemodynamic data required for the primary analysis;
Other
- Invalid or poor-quality ambulatory blood pressure monitoring (ABPM) recordings;
- Inability to obtain reliable carotid-femoral pulse wave velocity (cf-PWV) measurements;
- Pregnancy;
- Refusal or inability to provide informed consent (for prospectively recruited participants).
Who the study is looking for
- Adults aged 18 to 65 years;
- Both sexes;
- Referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation;
- Not receiving antihypertensive medication at the time of assessment;
- Availability of valid 24-hour ABPM data;
- Availability of carotid-femoral pulse wave velocity (cf-PWV) measurement;
- Availability of fasting laboratory data, including glucose and triglycerides, for calculation of the triglyceride-glucose (TyG) index;
- Ability and willingness to provide written informed consent (for prospectively recruited participants).
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medicine School of São José do Rio Preto Coordinator of this site? Confirm its status | São José do Rio Preto | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.